Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD8601 Phase I Safety and PD in T2DM
NCT02935712Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2016
- Primary completion
- Aug 2017
- Modality
- mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of AZD-8601 in diabetic foot ulcer (DFU) (2 arms), sponsored by AstraZeneca. Primary endpoints: Safety of AZD8601 by assessing summary of adverse events (Part A), Safety of AZD8601 by assessing number of subjects with clinically significant blood pressure (Part A) and 12 more. Started Dec 2016; status: completed.
02
Drugs
AZD-8601
03
Conditions
diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on NCT02935712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02935712.